91996-63-3

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-7-methylimidazo[4,5-b]pyridine is used as a chemical intermediate for the preparation of 6-methyl-7-deaza analog of adenosine, a compound that exhibits potent inhibitory effects on the replication of Polio and Dengue viruses. This makes it a valuable component in the development of antiviral medications and treatments.

Upstream product

• 98198-48-2 2-amino-5-bromo-4-methylpyridine 

Downstream Products

• 117888-98-9 6-bromo-1(3)H-imidazo[4,5-b]pyridine-7-carboxylic acid 
• 944718-24-5 6-Bromo-3-(4-chloro-benzenesulfonyl)-7-methyl-3H-imidazo[4,5-b]pyridine 

Relevant academic research and scientific papers

Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses

Bioisosteric deaza analogues of 6-methyl-9-β-d-ribofuranosylpurine, a hydrophobic analogue of adenosine, were synthesized and evaluated for antiviral activity. Whereas the 1-deaza and 3-deaza analogues were essentially inactive in plaque assays of infectivity, a novel 7-deaza-6-methyl-9-β-d- ribofuranosylpurine analogue, structurally related to the natural product tubercidin, potently inhibited replication of poliovirus (PV) in HeLa cells (IC50 = 11 nM) and dengue virus (DENV) in Vero cells (IC50 = 62 nM). Selectivity against PV over cytotoxic effects to HeLa cells was >100-fold after incubation for 7 h. Mechanistic studies of the 5′-triphosphate of 7-deaza-6-methyl-9-β-d-ribofuranosylpurine revealed that this compound is an efficient substrate of PV RNA-dependent RNA polymerase (RdRP) and is incorporated into RNA mimicking both ATP and GTP.